Curis Inc., of Lexington, Mass., re-initiated dosing in the phase I single-agent trial of CUDC-427 in patients with advanced and/or refractory solid tumors or lymphomas. CUDC-427 is an oral small molecule that is designed to promote cancer cell death by antagonizing an inhibitor of apoptosis proteins that support survival of cancer cells. (See BioWorld Today, Nov. 7, 2013.)